Onward raises $54m to continue neuromodulation trials
Onward Medical has raised $54m (€50m) via a bookbuild offering, with proceeds going towards ongoing clinical studies and an expected…
Onward Medical has raised $54m (€50m) via a bookbuild offering, with proceeds going towards ongoing clinical studies and an expected…
Amylyx Pharmaceuticals has announced positive topline results from the Phase II HELIOS clinical trial, indicating sustained improvements with AMX0035 in…
Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) has helped pre-symptomatic babies reach rare milestones after two years of treatment…
Cassava Sciences is moving forward with Phase III trials after paying $40m to settle an SEC case alleging misleading data…
Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate.…
This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of…
Bayer subsidiary BlueRock Therapeutics has reported encouraging 24-month outcomes from the Phase I exPDite clinical study of the bemdaneprocel cell…
AbbVie’s recently acquired Parkinson’s disease candidate tavapadon significantly reduced the burden of disease in a Phase III trial. The Phase…
Clinical-stage biotechnology company ProJenX has announced a collaboration with Unlearn to implement generative AI technology for a Phase I PRO-101…
Teva Pharmaceuticals has shared new safety data from the Phase III SOLARIS trial and a Phase I study of extended-release…